New data show the Swift system reduces blistering, discomfort, and recovery time while maintaining strong clinical outcomes for common and plantar warts.
Emblation, specializing in medical microwave technology, has received US Food and Drug Administration 510(k) clearance for expanded indications of its Swift and SwiftPro Systems, confirming their use for the treatment of common and plantar warts.
The clinical study conducted confirmed that Swift patients experience less blistering, itching, tingling, discolouration, and hypersensitivity and about half the pain compared to cryotherapy while achieving strong clinical outcomes.
“This FDA 510(k) clearance cements what thousands of clinicians already know: Swift delivers better outcomes with less pain than traditional methods, while being safer and more tolerable for patients,” says Ian Stevens, CEO of Emblation, in a release. “We’re thrilled to expand access to treatment for US patients and reaffirm its value across the UK and beyond.”
Swift’s targeted microwave energy treats viral lesions without breaking the skin, offering a clean, non-invasive alternative to traditional destructive methods, such as cryotherapy, that can slow recovery and increase discomfort.
“Swift should always be the first choice for treating common and plantar warts. We’ve relied on it for years, clearing cases in months instead of the years traditional treatments can take,” says Dr Robert M. Conenello, Orangetown Podiatry, NY, in a release. “This FDA recognition is incredibly well-deserved.”
Based in Stirling, UK, Emblation launched Swift in 2016.
Photo caption: Swift Pro
Photo credit: Emblation
